Nevertheless, owing to the complexity of CXCR4 interaction in the TME, combinatorial treatment of CXCR4 with chemotherapy, immunotherapy, or stromal targeting agents is required to achieve maximum therapeutic effect for lung cancer patients. This evidence concerns the gene CXCR4 and lung carcinoma.